|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
9/3/2009 1:30:26 PM
Thursday 3 September 2009 - Adelaide, Australia: Bionomics Limited (ASX:BNO) today announced that it has entered into a Subscription Agreement with Start-up Australia Ventures Pty Ltd as trustee of the Start-up Australia Trust (Start-up) for a $7 million placement of ordinary shares to Start-up.
Start-up has access to funding from the Australian Government’s Innovation Investment Follow-on Fund for the purpose of taking up the placement.
Dr George Jessup, Managing Director of Start-up, commented “I am delighted with the continued progress of Bionomics. The company has two exciting new drugs in clinical trials and a high value partnership with a major European pharmaceutical company. They have achieved this with a very efficient use of shareholder funds. This new funding will allow the company to achieve critical value adding milestones for investors and is also important for patients who are in need of these drugs."
The placement to Start-up is conditional on:
(a) Bionomics’ shareholders resolving at a general meeting to approve, for the purposes of item 7 of section 611 of the Corporations Act, the acquisition of the placement shares by Start-up; and
(b) Bionomics raising a further $5 million through private placements to institutional or sophisticated investors.
About Bionomics Limited
Bionomics (ASX: BNO) discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. Bionomics' most advanced program, BNC105 for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, the company's angiogenesis target and drug discovery platform, incorporates a variety of genomics tools to identify and validate novel angiogenesis targets. MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system.
|
|
|
|
|
|
|
|
|
|
|